OncoMatch/Clinical Trials/NCT06516445

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

Is NCT06516445 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Fluzoparib for colorectal cancer.

Phase 2RecruitingHuazhong University of Science and TechnologyNCT06516445Data as of May 2026

Treatment: Camrelizumab · Fluzoparib · CAPEOX — To explore the safety and efficacy of neoadjuvant therapy for locally advanced rectal cancer with short course radiotherapy followed by camrelizumab combined with fluzoparib and chemotherapy

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Disease stage

Required: Stage T3NANYM0, T4NANYM0 (AJCC 8th edition)

Clinical Stage (according to the 8th edition of AJCC) T3NanyM0 ... or T4NanyM0

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiotherapy

Any radiotherapy ... directed against the tumor

Cannot have received: chemotherapy

Any ... chemotherapy ... directed against the tumor

Cannot have received: antineoplastic drug

Any ... other antineoplastic drug directed against the tumor

Lab requirements

Blood counts

White blood cell count ≥ 4.0 x 10^9/L; Neutrophil count ≥ 1.5 x 10^9/L; Platelet count ≥100×10^9/L; Hemoglobin ≥90 g/L

Kidney function

Serum creatinine ≤ 1.5 x ULN, or creatinine clearance ≥ 50 mL/min (Cocheroft-Gault formula)

Liver function

Total bilirubin ≤ 1.5 x ULN; ALT ≤ 2.5×ULN, AST ≤ 2.5×ULN

Normal function of major organs, including: ... blood tests ... Blood biochemistry ... Coagulation: INR ≤ 1.5 x ULN; APTT ≤ 1.5×ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify